SEC For	m 4																		
FORM 4 UNITED				STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHI										HIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person* <u>Yedid Robert A.</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Vaxart, Inc.</u> [ VXRT ]									ck all applic Director	able) r	10% Owner		vner	
(Last) (First) (Middle) C/O VAXART, INC. 385 OYSTER POINT BOULEVARD, SUITE 9A				)A	3. Date of Earliest Transaction (Month/Day/Year) 06/08/2020									Officer (give title Other (specify below) below)				pecify	
(Street) SOUTH SAN FRANCISCO			94080		4. If Amendment, Date of C				of Original Filed (Month/Day/Year)			Line)	ndividual or Joint/Group Filing (Check Applicable ) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	,	(Zip) Die I - Nor	n-Deriv	ative	Se	curitie	s Ad	cquired,	Dis	posed o	f, or	Benef	ficially	/ Owned				
1. Title of Security (Instr. 3) 2. Tran Date			2. Trans	action	ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			A) or	) or 5. Amoun		Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	() ()	A) or D)	Price	Transact (Instr. 3 a	action(s)			(Instr. 4)
			Table II -								osed of, convertik				Owned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Execution Date, ear) if any		l. Transaction Code (Instr. I)		of		6. Date Exercisa Expiration Date (Month/Day/Yea		9	of Securities		curity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					ode \	,	(4)		Date		Expiration	Title	or Ni of	umber					

Explanation of Responses:

\$2.39

Stock Option (right to buy)

1. The shares subject to this option shall vest on the first anniversary of the 2020 annual meeting of stockholders of the Issuer.

<u>/s/ Wouter W. Latour, M.D.,</u> <u>Attorney-in-Fact for Robert A.</u> 06/09/2020

65,700

\$<mark>0</mark>

65,700

D

Common Stock

<u>Yedid</u>

06/07/2030

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/08/2020

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

65,700

06/08/2021(1)

## POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Wouter W. Latour, M.D., and Josh Seidenfeld, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc. (the "*Company*"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "*Exchange Act*") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 (including any amendments thereto) and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of October 25, 2019.

/s/ Robert A. Yedid Robert A. Yedid